Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
In the late 1990s, as a response to rising antimicrobial resistance (AMR), an independent multinational, interdisciplinary group was formed specifically targeting primary care antibiotic prescribing for community-acquired respiratory tract infections (CA-RTIs). The group comprised senior clinicians from Canada, Israel, Spain, Sweden, UK and USA. The group's objectives were to provide recommendations for antibiotic stewardship in the community because, whilst it was widely accepted that inappropriate antibiotic use was contributing to AMR, it remained difficult to change prescribing behaviour. The group aimed to identify principles underlying appropriate antibiotic prescribing and guideline formulation to reduce morbidity from CA-RTIs, limit therapeutic failure and, importantly, curb AMR emergence. The group published a report in 2002, which has become known as the Consensus Principles. (i) To consider the relevance of the Consensus Principles in 2022 by reviewing current global approaches to rising AMR. A wide range of factors, such as antibiotic overuse, most recently seen in COVID-19 patients, are still driving rising AMR even though there has been a high-level international response to the AMR threat; and (ii) as an introduction to this Supplement, which reports the findings of analyses of how AMR is being addressed in nine disparate countries (Brazil, India, Kuwait, Mexico, Pakistan, Russia, Saudi Arabia, Türkiye and Vietnam). Understanding how these initiatives are being pursued in different countries helps identify areas where more information is needed. Adherence to the Consensus Principles remains as important now as it was in 2002. Achieving appropriate antibiotic prescribing is a vital objective in order that the right patient receives the right antibiotics at the right time to ensure optimal clinical outcomes while at the same time helping to limit further increases in AMR.
Sections du résumé
BACKGROUND
In the late 1990s, as a response to rising antimicrobial resistance (AMR), an independent multinational, interdisciplinary group was formed specifically targeting primary care antibiotic prescribing for community-acquired respiratory tract infections (CA-RTIs). The group comprised senior clinicians from Canada, Israel, Spain, Sweden, UK and USA. The group's objectives were to provide recommendations for antibiotic stewardship in the community because, whilst it was widely accepted that inappropriate antibiotic use was contributing to AMR, it remained difficult to change prescribing behaviour. The group aimed to identify principles underlying appropriate antibiotic prescribing and guideline formulation to reduce morbidity from CA-RTIs, limit therapeutic failure and, importantly, curb AMR emergence. The group published a report in 2002, which has become known as the Consensus Principles.
OBJECTIVES
(i) To consider the relevance of the Consensus Principles in 2022 by reviewing current global approaches to rising AMR. A wide range of factors, such as antibiotic overuse, most recently seen in COVID-19 patients, are still driving rising AMR even though there has been a high-level international response to the AMR threat; and (ii) as an introduction to this Supplement, which reports the findings of analyses of how AMR is being addressed in nine disparate countries (Brazil, India, Kuwait, Mexico, Pakistan, Russia, Saudi Arabia, Türkiye and Vietnam). Understanding how these initiatives are being pursued in different countries helps identify areas where more information is needed.
CONCLUSIONS
Adherence to the Consensus Principles remains as important now as it was in 2002. Achieving appropriate antibiotic prescribing is a vital objective in order that the right patient receives the right antibiotics at the right time to ensure optimal clinical outcomes while at the same time helping to limit further increases in AMR.
Identifiants
pubmed: 36065724
pii: 6692263
doi: 10.1093/jac/dkac211
pmc: PMC9445850
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
i2-i9Subventions
Organisme : GlaxoSmithKline
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
WMJ. 2020 Sep;119(3):185-189
pubmed: 33091293
J Antibiot (Tokyo). 2013 Oct;66(10):571-91
pubmed: 24002361
Ann Intern Med. 2016 Mar 15;164(6):425-34
pubmed: 26785402
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
J Antimicrob Chemother. 2020 Apr 1;75(Suppl 1):i2-i18
pubmed: 32337595
Arch Dis Child. 2017 May;102(5):450-457
pubmed: 27601361
J Antimicrob Chemother. 2005 Oct;56 Suppl 2:ii3-ii21
pubmed: 16282278
Front Microbiol. 2011 Nov 24;2:230
pubmed: 22164154
New Microbes New Infect. 2015 Apr 16;6:22-9
pubmed: 26029375
Drug Saf. 2011 Jun 1;34(6):465-88
pubmed: 21585220
Antimicrob Agents Chemother. 2013 Aug;57(8):4079
pubmed: 23669392
Nat Rev Microbiol. 2003 Oct;1(1):65-70
pubmed: 15040181
Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S139-41
pubmed: 18029150
J Hosp Infect. 2021 Jan;107:114-115
pubmed: 33217492
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
J Antimicrob Chemother. 2002 Jan;49(1):31-40
pubmed: 11751764
Lancet. 2013 May 11;381(9878):1606-9
pubmed: 23489756
J Clin Microbiol. 2022 Mar 16;60(3):e0027621
pubmed: 34346716
Nat Med. 2004 Dec;10(12 Suppl):S122-9
pubmed: 15577930
PLoS One. 2012;7(4):e34953
pubmed: 22509370
JAC Antimicrob Resist. 2021 Mar 27;3(1):dlab023
pubmed: 34223098
Clin Infect Dis. 2012 Apr;54(8):e72-e112
pubmed: 22438350
Int J Infect Dis. 2021 Mar;104:250-254
pubmed: 33434666
J Antimicrob Chemother. 2000 Sep;46 Suppl T2:53-8
pubmed: 11065148
Pediatrics. 2010 Feb;125(2):214-20
pubmed: 20100746
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Indian J Med Res. 2019 Feb;149(2):87-96
pubmed: 31219073
Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S21-31
pubmed: 18713046
Clin Microbiol Infect. 2002;8 Suppl 2:12-42
pubmed: 12427206
Pharmacology. 2008;82(3):171-9
pubmed: 18679046
Environ Sci Eur. 2021;33(1):11
pubmed: 33532166
Drugs. 2006;66(7):893-901
pubmed: 16740004
Lancet. 2003 Nov 22;362(9397):1726-7
pubmed: 14655659
J Infect Public Health. 2021 May;14(5):555-560
pubmed: 33848884
Antibiotics (Basel). 2019 Apr 24;8(2):
pubmed: 31022923
Int J Infect Dis. 2005 Sep;9(5):262-73
pubmed: 16023881
J Antimicrob Chemother. 2016 May;71 Suppl 1:i3-19
pubmed: 27048580
Antimicrob Agents Chemother. 2006 Nov;50(11):3646-50
pubmed: 16940064
Braz J Infect Dis. 2004 Feb;8(1):25-79
pubmed: 15286878
Curr Opin Crit Care. 2020 Oct;26(5):433-441
pubmed: 32739970
Curr Opin Pharmacol. 2011 Oct;11(5):477-85
pubmed: 21840259
Clin Drug Investig. 2020 Oct;40(10):989-990
pubmed: 32816219
Infection. 2021 Feb;49(1):29-56
pubmed: 33367978
Semin Respir Crit Care Med. 2012 Jun;33(3):298-310
pubmed: 22718216
Infect Dis Clin North Am. 2016 Jun;30(2):313-322
pubmed: 27208761